<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03936699</url>
  </required_header>
  <id_info>
    <org_study_id>CD-005</org_study_id>
    <nct_id>NCT03936699</nct_id>
  </id_info>
  <brief_title>ELIRA 2: Safety and Effectiveness of TENS Assisted Weight Loss and Appetite Suppression</brief_title>
  <acronym>ELIRA_2</acronym>
  <official_title>Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss and/or Appetite Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elira Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elira Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to demonstrate safety and effectiveness of a wearable patch
      TENS system (Appendix 2) in driving weight loss and appetite suppression when coupled with an
      integrated weight loss reduction strategy. The study is designed to demonstrate that TENS
      stimulation sufficient to drive weight loss and appetite suppression is safe and tolerable
      when compared to standard of care, and that adverse events/adverse device effects are similar
      to other TENS device use cases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, adaptive parallel arm study. Subjects will be initially screened during a
      screening period (+/- 7 days). During this screening period, subjects will sign an Informed
      Consent Form (ICF), have their weight/height and blood pressure measured as part of a
      physical exam, take a pregnancy test (females of child bearing potential), get blood drawn
      for analysis (blood lipids, HbA1c), and complete the PHQ-9 and pre-study survey.

      At the end of the screening period, eligible subjects will be enrolled/randomized in the
      study and be randomized to either a treatment or control group. After enrolling, both control
      and treatment subjects will be instructed to follow a healthy diet and reduce calories as
      desired for the duration of the study and will receive training on the use of the electronic
      scale and completion of paper diaries. For the treatment group, subjects will be instructed
      on use of the Elira wearable patch system. Photographs will be taken at the enrollment visit.
      Following this, subjects will enter the Therapy Period for ~24-weeks.

      At the 12 week visit, subjects will be assessed for weight loss, blood pressure, blood
      lipids, HbA1c, patient preference questionnaire and their participation will continue through
      months 4-6 for the Safety phase of the Therapy Period. The Therapy Period will be considered
      complete (pending laboratory results, adverse events or serious adverse events). Patient
      (treatment) photographs will also be taken at the 12 week visit.

      The study utilizes an adaptive approach where cohorts of enrolled/randomized subjects (in
      groups of ~25 per arm) are assessed for dose response and progression to achievement of
      primary and secondary endpoints. Frequent interim endpoint assessment utilizing Markov-chain
      Monte Carlo (MCMC) methods coupled with Longitudinal analyses will be utilized to determine
      sample sizes for future cohorts (assessed primarily via Normal dynamic linear modeling
      [NDLM]). Long term safety of the device will be shown through 6 months of usage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, adaptive parallel arm study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Treatment Emergent Adverse Events [Time Frame: 12 weeks] Safety/Tolerability will be assessed by the non-inferiority of incidence of serious adverse events (SAEs), unanticipated serious adverse events (USAEs), device-related SAEs (DSAEs), and unanticipated device-related SAEs (UDAEs) that are associated with the TENS therapy throughout the stimulation and the follow-up period versus historical control (compared with other TENS systems).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in appetite as measured by a visual analogue scale before and after meals</measure>
    <time_frame>3 months</time_frame>
    <description>Appetite Changes [Time Frame: 12 weeks] Percent change in appetite scores at the end of the trial compared to Baseline between Treatment and Control.
Subjects are asked to score level of hunger on a Visual Analogue Scale of 1 to 100 before and after meals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Total Body Weight Loss</measure>
    <time_frame>3 months</time_frame>
    <description>Percent reduction in total body weight loss (%TBWL), measured as End Weight - Initial Weight, multiplied by 100, at the end of Experimental period compared to Baseline between Treatment and Control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in BMI</measure>
    <time_frame>3 months</time_frame>
    <description>Percent changes in BMI at the end of Experimental period compared to Baseline between Treatment and Control.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatome for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous Nerve Stimulator (TENS)</intervention_name>
    <description>The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
Behavioral: Diet &amp; Exercise Subjects to be instructed on a healthy 1200 calorie diet.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet &amp; Exercise</intervention_name>
    <description>Subjects to be instructed on a healthy 1200 calorie diet.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is between 18 - 65 years of age inclusive.

          2. Subject has a BMI of 25-35 kg/ m2 inclusive.

          3. Subject has signed the informed consent form and is able to comply with study protocol
             and adhere to study visit schedule.

          4. Subject is able to wear and use a wearable, patch TENS system.

          5. Subject is able to use a touch screen hand held smart phone.

          6. Subject is fluent in English and can complete questionnaires.

          7. Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at
             screening or enrollment visit, prior to placement of ELIRA device.

          8. Subject is male or non-pregnant, non-lactating female, who agrees to use effective
             contraceptive methods throughout the length of the trial based on PI approval.

        Exclusion Criteria:

          1. Subject has any known gastrointestinal disorder that in the opinion of the PI
             precludes enrollment into the trial.

          2. Subject has had a prior bariatric procedure or any previous procedure on the stomach.

          3. Subject has any significant multisystem disease in the opinion of the PI.

          4. Subject has &gt; 6.5 HbA1c.

          5. Subject has significant cardiac arrhythmia, ectopy, or significant cardiovascular
             disease.

          6. Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD).

          7. Subject is a female of child-bearing potential who is pregnant or intends to become
             pregnant during the trial period.

          8. Subject has current and/or a history of cancer within the past 5 years (not including
             basal cell carcinoma or cervical carcinoma in situ).

          9. Subject has had a weight change of + 5% of his/her Total Body Weight in the 3 months
             prior to screening.

         10. Subject has a moderate / severe psychiatric disorder.

         11. Subject has a diagnosed neurological disease.

         12. Subject has a diagnosed eating disorder.

         13. Subject has a skin disorder affecting the thoracic dermatomes.

         14. Subject has active or /has ever had shingles in the abdominal area.

         15. Subject has abdominal surgery or other scars which may interfere with TENS stimulation
             in the opinion of the PI.

         16. Subject is currently enrolled in other potentially confounding research.

         17. Subject has known allergic reaction to materials in the TENS electrodes and/or is
             otherwise unable to tolerate stimulation with the wearable TENS system. This includes
             known allergies to latex, nickel and/or hydrogels.

         18. Subject has a history of sensitive skin, including eczema wheel-and-flare or other
             skin irritation, per PI discretion.

         19. Subject is actively participating or unwilling to discontinue participation in another
             weight loss program. Subjects may not enroll in paid or unpaid programs that involve
             in-person or online apps or coaching, beginning new fitness regimens or utilizing meal
             planning or paid nutritional coaching during the course of the ELIRA study

         20. Subject is taking weight loss control medications including but not limited to Over
             The Counter (OTC) medications, Metformin, and Belviq. (See Appendix 8)

         21. Subject is planning any major medical treatments or surgeries that could cause weight
             loss.

         22. Subject is unable to take anti-nausea medications planned for the study.

         23. Inability to walk at least 0.8 kilometers per day (10 minutes of continuous walking).

         24. Current smoker or user of nicotine product or smoking cessation within 1 year of the
             screening date.

         25. History of treatment for or current abuse of drug or alcohol.

         26. A score of â‰¥10 on the Patient Health Questionnaire 9 (PHQ-9), demonstrating moderate
             depression.

         27. Any subject that the investigator considers inappropriate for the study for medical
             reasons.

         28. Subject has a history of moderate/severe migraines or other severe headache disorders
             requiring the treatment of Topiramate.

         29. Subject is on drug therapy which may alter antral motility or appetite, per PI
             discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brad Stengel</last_name>
    <phone>3144823911</phone>
    <email>stengelbrad@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West County OB/GYN Specialists</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Bruchas</last_name>
      <phone>206-399-0275</phone>
      <email>casolutions3@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Laura Pignotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>May 1, 2019</last_update_submitted>
  <last_update_submitted_qc>May 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

